September 22, 2017
Agilvax to Attend 10th Annual BioPharm America & RESI Boston Conferences
ALBUQUERQUE, NM – September 22, 2017 – Agilvax Inc., a biotechnology company that develops targeted cancer immunotherapies and vaccines, announced today that Federica Pericle, President & CEO, will be attending the 10th Annual BioPharm America Conference in Boston, MA, September 26-27, 2017. Additionally, Les Stewart, Chief Operations Officer, will be attending the RESI Boston Conference in Boston, MA, September 26, 2017. Agilvax will be available for one-on-one meetings, and gladly welcomes the opportunity to discuss Agilvax’s immunotherapy and vaccine programs in more detail.
Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critical role in the high rates of recurrence and poor outcomes in TNBC as compared with other forms of breast cancer. The company’s pipeline and drug discovery platform is based on VLPs derived from RNA bacteriophage that have been engineered to display antigens in an ordered geometric pattern, which can be utilized to stimulate robust and specific immune responses to both foreign pathogens and self-antigens. The Company was founded in 2011 and has headquarters in Albuquerque, NM, and offices in El Paso, TX.